Investment Thesis
AbbVie demonstrates strong operational efficiency with 24.6% operating margins and robust free cash flow generation of $17.8B, but faces significant financial constraints from negative stockholders' equity (-$3.3B) and high debt levels ($64.5B) that limit financial flexibility. Revenue growth stagnation (0.0% YoY) combined with deteriorating liquidity ratios (0.67x current ratio) raises concerns about sustainability despite solid cash generation and profitability.
ABBV Strengths
- Exceptional operating cash flow of $19.0B with 29.1% FCF margin demonstrates strong underlying business quality
- High operating margin of 24.6% and gross margin of 19.7% indicate pricing power and operational efficiency in pharmaceutical sector
- Robust interest coverage ratio of 5.2x suggests adequate debt servicing capability despite leverage concerns
ABBV Risks
- Negative stockholders' equity of -$3.3B indicates balance sheet deterioration and potential shareholder value destruction from previous capital allocation decisions
- Weak liquidity position with current ratio of 0.67x and quick ratio of 0.56x creates refinancing and operational flexibility risks
- Stagnant revenue growth (0.0% YoY) combined with flat EPS growth (-1.3% YoY) suggests pipeline weakness or maturation of product portfolio in competitive pharmaceutical market
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Stockholders' equity recovery and debt reduction from FCF generation
- Working capital trends and current ratio improvement given liquidity concerns
ABBV Financial Metrics
Revenue
$61.2B
Net Income
$4.2B
EPS (Diluted)
$2.36
Free Cash Flow
$17.8B
Total Assets
$134.0B
Cash Position
$5.2B
ABBV Profitability Ratios
Gross Margin
19.7%
Operating Margin
24.6%
Net Margin
6.9%
ROE
N/A
ROA
3.2%
FCF Margin
29.1%
ABBV Balance Sheet & Liquidity
Current Ratio
0.67x
Quick Ratio
0.56x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
5.21x
Long-term Debt
$64.5B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 17, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI